BLACK FRIDAY 75% OFF Go Premium in Our Biggest Sale Ever UPGRADE NOW X

Type Expert or S 75% OFF Ideas Tools Screeners Dividends Experts Portfolio News Private Companies More Plans

Actinogen reports XanaMIA trends toward benefit in older Alzheimer's patients

TipRanks Australian Auto-Generated Newsdesk
Nov 19,

Analyze A+ A- More Market News >



Image source: Shutterstock

Story Highlights

- XanaMIA showed older participants had 30% disease slowing.

Latest News Feed

Skydance Stock (NYSE:SKYD) Down Over 5% as it Bows Out of World Cup Rights
5m ago SKYD

Anthropic Stock Is Attracting Over $1 Billion in Retail Trading. Here's What's...
15m ago AMD ANT

Ford Stock (NYSE:F) Gets Upgrade at DZ Bank, Share Prices Slip
47m ago F

Stock Market Selloff Hits Every Sector as Consumer Stocks Lead Declines
59m ago XLB XLC

Wedbush Lifts Nvidia Stock (NVDA) Price Target to $293. Here's Why
1h ago NVDA

Walmart (WMT) and Costco (COST) Stocks Could Benefit from Tech Outages...
1h ago UAL WMT

More Articles


Market News
Stock Market Selloff Hits Every Sector as Consumer...
59m ago XLB XLC


Market News
Wedbush Lifts Nvidia Stock (NVDA) Price Target to $2...
1h ago NVDA


Market News
Walmart (WMT) and Costco (COST) Stocks Could...
1h ago UAL WMT

Ask Samuel AI

Stock Comparison

- Xanamem remained safe and well tolerated over 36 weeks.
- Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Add AU:ACW to your watchlist and never miss an update about AU:ACW stock!

The latest announcement is out from Actinogen Medical (ACW -82.22% ▼).

Actinogen Medical is developing oral emestedastat (Xanamem) for mild to moderate Alzheimer's disease. Its 36-week, placebo-controlled XanaMIA trial enrolled 247 patients with elevated pTau181 blood biomarker levels.

In the overall population, Xanamem was numerically but not statistically superior to placebo on delayed disease progression, while participants above the median

Quantum Computing AI Cryptocurrency Bitcoin Stocks Dividend Value Biotech Oil Chinese Chat GPT Banks Airline Beer & Beverages Energy

Investment Ideas

Analyst Top Stocks Smart Score Stocks Stock Screener Top Wall Street Analysts Insiders' Hot Stocks Top Penny Stocks Unusual Options Activity Top ETFs by Upside Potential

age of 75 showed a statistically significant zero-progression-rate benefit and clinically significant 30% disease slowing. The treatment was safe and well tolerated over 36 weeks, with no serious adverse events attributed to Xanamem; early open-label extension data showed no mean progression after 24 weeks in 29 participants.

PROMOTION

BLACK FRIDAY SALE

- Get 75% Off TipRanks Premium and unlock powerful investing tools to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and

discover new investing opportunities with data-backed stock picks

Learn more about TipRanks Premium



The most recent analyst rating on ACW -82.22% ▼ stock is a Buy with a A$0.08 price target.
To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical is developing an oral Alzheimer's disease treatment, emestedastat (Xanamem), for patients with mild to moderate disease.

Average Trading Volume:
5,527,206

Technical Sentiment Signal: Hold

Current Market Cap: A$174.1M

Learn more about ACW stock on TipRanks' Stock Analysis page.

Trending Articles:

- Skydance Stock (NYSE:SKYD) Down Over 5% as it Bows Out of World Cup Rights
- Ford Stock (NYSE:F) Gets Upgrade at DZ Bank, Share Prices Slip
- Intel Lands First Customer for 18A Process, Intel Stock (NASDAQ:INTC) Gains

This article was AI-generated from the company's official filing, with automated quality checks and editorial spot-checks.

Disclaimer & Disclosure Report an Issue

Become a better investor. Download your free research report on Actinogen Medical stock today!

Actinogen Medical (ACW) 12-Month Analyst Forecast



Related Articles

Actinogen Securities...

Actinogen Medical...

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!

Conversation 0 Comments Sort by

Your voice matters. Discussions are moderated for civility. Read our guidelines here .

Log in to join the conversation

Log in

No comments yet. Be the first to share your thoughts!

Palo Alto Networks Stock Jumps as AI Cyber Threats Create New Growth Opportunity



Vince Condarcuri
Nov 20,

Analyze A+ A-

Add as preferred source



Image source: Shutterstock

Story Highlights

- Palo Alto Networks warns that serious software vulnerabilities are being discovered

at nearly seven times last year's monthly average.
- AI-assisted hackers targeted 19 organizations, while Palo Alto's Prisma AIRS security product has reached nearly $170 million in annual recurring revenue.
- Wall Street analysts have a Strong Buy consensus rating on PANW stock, with an average price target of $423.43.

Shares of cybersecurity company Palo Alto Networks PANW +0.18% ▲ jumped on

Continue Reading

TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.

NEWSLETTER SUBSCRIPTION

Enter your email to receive our newsletter

Email address SIGN UP

I agree to TipRanks Terms of use and Privacy Policy

Terms of Use Privacy Policy FAQ

Do not sell or share my personal information

Education

How To Use TipRanks
TipRanks Labs
Glossary
FAQs

About us

About TipRanks
TipRanks' Editorial Policy
Careers
Contact Us
Reviews

Working With TipRanks

Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire

Plans

Plans & Pricing
Smart Investor Newsletter
Smart Dividend Newsletter
API for Institutions
MCP for Agents

Calendars

Earnings Calendar
Dividend Calendar
Economic Calendar
Stock Split Calendar

Calculators

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Screeners

Stock Screener
ETF Screener
Penny Screener
Technical Analysis Screener

Find Us on

Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.